T-cell engagers are a branch of immunotherapy that has undergone considerable change since their clinical inception. Andrew J Souers, VP, Oncology Discovery Research at AbbVie, elucidates the current understanding of their biology and expanding focus areas of application.

This webinar examines the design trade-offs and technical constraints involved in building a high-throughput robotic imaging pipeline for complex biological workflows.

Northwestern scientists have grown human spinal cord organoids to test therapies that could reduce scarring and promote nerve regrowth in patients.

Scientists have developed an AI-enhanced imaging platform that enables non-invasive, label-free and longitudinal monitoring of cancer organoids and spheroids.

Scientists have identified a brain circuit that connects contextual memory with appetite, advancing understanding of binge eating and obesity while highlighting a promising new target for drug discovery.

Researchers at the University of Pittsburgh School of Medicine have developed a new approach for tackling insulin resistance and type 2 diabetes by protecting beneficial immune cells in fat tissue.

Scientists have identified a previously unknown lysosomal signalling pathway that drives growth in drug-resistant SHH medulloblastoma, which could lead to more precise and less harmful treatments for children with aggressive brain tumours.

An international team of scientists is urging researchers to put ageing at the centre of Parkinson’s studies, arguing that it has been overlooked for too long.

Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.

Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing, this report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.

Biomarkers are redefining how precision therapies are discovered, validated and delivered. This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.